Showing results (141-150 of 152) with videos related to
Sort By:
Pageof 16
Neurobiology of Aging|July 18, 2021
A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT geneDiana A Olszewska, Conor Fearon, Christopher McGuigan, et al.Irish Journal of Medical Science|June 21, 2020
Moyamoya disease and moyamoya syndrome in Ireland: patient demographics, mode of presentation and outcomes of EC-IC bypass surgeryRonan J Doherty, John Caird, Darach Crimmins, et al.Journal of Medicinal Chemistry|June 10, 2010
Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo propertiesChristopher McGuigan, Arnaud Gilles, Karolina Madela, et al.Neurology. Clinical Practice|January 29, 2021
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MSAndrew Chan, John Rose, Enrique Alvarez, et al.Bioorganic & Medicinal Chemistry Letters|March 5, 2013
Synthesis and evaluation against hepatitis C virus of 7-deaza analogues of 2'-C-methyl-6-O-methyl guanosine nucleoside and L-Alanine ester phosphoramidatesClaire Bourdin, Christopher McGuigan, Andrea Brancale, et al.Antimicrobial Agents and Chemotherapy|March 2, 2011
INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic propertiesJohn H Vernachio, Blair Bleiman, K Dawn Bryant, et al.Journal of Medicinal Chemistry|November 2, 2011
Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agentsChristopher McGuigan, Karolina Madela, Mohamed Aljarah, et al.Journal of Neurology|November 5, 2015
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromesMaciej Juryńczyk, Brian Weinshenker, Gulsen Akman-Demir, et al.The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.Pageof 16